SGLT2 inhibitors may enable continuation of RAAS inhibitors for hypertension treatment, which is linked with better kidney and cardiovascular outcomes.

The prophylactic efficacy of TMP-SMX was significantly higher in subgroups with baseline lymphopenia, azotemia, microscopic polyangiitis, or relapsed AAV.

Geographic disparities seen, with greater percentage of cardiovascular deaths attributable to di-2-ethylhexylphthalate exposure for South Asia, Middle East.

Patients with diabetic macular edema treated with intravitreal aflibercept have a significantly higher risk of adverse renal events compared with those treated with ranibizumab.

(HealthDay News) — The number of kidney transplants performed annually in the United States has increased steadily, but with decreasing allocation efficiency, according to a study published online in ...

Sustainable development efforts such as lowering out-of-pocket health expenses can reduce future prevalence of AMR by 5.1 percent.

(HealthDay News) — For female patients with multiple sclerosis (MS), transcutaneous posterior tibial nerve stimulation (TPTNS) and repetitive transcranial magnetic stimulation (rTMS) are comparable ...

Addition of revascularization to optimized medical therapy not beneficial in patients with carotid stenosis ≥50 percent and low or intermediate predicted stroke risk.

The new initiative will focus on research using the beta-propiolactone vaccine platform. (HealthDay News) — The U.S. Department of Health and Human Services and the National Institutes of Health ...

Illness severity, comorbidities, and prior exposure to antibiotics associated with hospital-onset antimicrobial resistant infections. (HealthDay News) — Hospital-onset antimicrobial-resistant ...

Authors say findings do not support routine hormone use in the perimenopausal and postmenopausal periods. (HealthDay News) — Hormone therapy use is linked to worse bladder health in ...

SGLT-2 inhibitor use, compared with DPP-4 inhibitor use, was associated with a lower incidence of epilepsy among patients with type 2 diabetes. The use of sodium-glucose cotransporter 2 (SGLT-2 ...